GLPG Stock Overview
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €25.52 |
| 52 Week High | €38.74 |
| 52 Week Low | €22.06 |
| Beta | 0.094 |
| 11 Month Change | -6.25% |
| 3 Month Change | 10.57% |
| 1 Year Change | -25.75% |
| 33 Year Change | -45.31% |
| 5 Year Change | -84.72% |
| Change since IPO | -70.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| GLPG | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 3.3% | 1.6% | -1.4% |
| 1Y | -25.7% | 7.7% | 2.7% |
Return vs Industry: GLPG underperformed the Austrian Biotechs industry which returned 7.7% over the past year.
Return vs Market: GLPG underperformed the Austrian Market which returned 2.7% over the past year.
Price Volatility
| GLPG volatility | |
|---|---|
| GLPG Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in AT Market | 6.1% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: GLPG's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: GLPG's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 683 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
| GLPG fundamental statistics | |
|---|---|
| Market cap | €1.68b |
| Earnings (TTM) | -€60.61m |
| Revenue (TTM) | €260.09m |
6.5x
P/S Ratio-27.8x
P/E RatioIs GLPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLPG income statement (TTM) | |
|---|---|
| Revenue | €260.09m |
| Cost of Revenue | €331.48m |
| Gross Profit | -€71.38m |
| Other Expenses | -€10.77m |
| Earnings | -€60.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -27.45% |
| Net Profit Margin | -23.30% |
| Debt/Equity Ratio | 0% |
How did GLPG perform over the long term?
See historical performance and comparison